Evidence map›Paper›PMID 36581744›Full record

ArticleEndocrine2023

The performance of levothyroxine tablet is impaired by bariatric surgery.

Pierpaolo Trimboli, Nicola Ossola, Alessandro Torre, Francesco Mongelli, Massimo Quarenghi, Chiara Camponovo, Barbara Lucchini, Mario Rotondi, Lorenzo Ruinelli, Fabio Garofalo

Open access · hybridAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Review
  4. Observational
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Pierpaolo TrimboliServizio di Endocrinologia e Diabetologia, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland. pierpaolo.trimboli@eoc.ch.ORCID 0000-0002-2125-4937
Nicola OssolaServizio di Nutrizione Clinica e Dietetica, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Alessandro TorreServizio di Chirurgia, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Francesco MongelliServizio di Chirurgia, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Massimo QuarenghiServizio di Nutrizione Clinica e Dietetica, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Chiara CamponovoServizio di Endocrinologia e Diabetologia, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Barbara LucchiniServizio di Endocrinologia e Diabetologia, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Mario RotondiUnit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
Lorenzo RuinelliTeam Data Science & Research, Area ICT, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Fabio GarofaloServizio di Chirurgia, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Ente Ospedaliero Cantonale · CHUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim was to evaluate if bariatric surgery can affect the LT4 performance. The endpoints were the following: 1) difference between LT4 daily dose before and 1 year after surgery, 2) difference between LT4 dose per weight before and 1 year after surgery, 3) difference among LT4 preparations.

methodsThe study period was between January 2018 and May 2022. Inclusion criteria were a) adults undergone bariatric surgery, b) with proven autoimmune hypothyroidism, c) on LT4 therapy before bariatric surgery, d) using any commercialized LT4 preparation. Excluded were patients a) proven to have or suspected for pre-surgical intestinal malabsorption, b) with other potential interfering factors on LT4 absorption; c) with heart, renal, and/or hepatic failure, d) with recent/current infection/inflammation, e) in pregnancy, f) with incomplete data about LT4 therapy.

resultsAccording to the selection criteria, 40 patients were included. Both TSH and LT4 daily doses were not significantly different with respect to baseline values. On the contrary, the LT4 dose per weight was significantly increased, especially in RYGB patients. An increased LT4 dose per weight was observed with the reduction of weight.

conclusionOne year after bariatric surgery 1) the daily dose of LT4 remains unchanged, and 2) despite the significant weight reduction, LT4 dose per weight increases. Most data are referred to LT4 tablet and the performance of LT4 caps should be further investigated.

Indexed as

Bariatric SurgeryHypothyroidismAdultFemaleHumansPregnancyTabletsThyrotropinThyroxineWeight LossTabletsThyrotropinThyroxineBariatric surgeryFormulationsHypothyroidismLevothyroxineTablet

Identifiers

PMID36581744
PMCPMC10199827
OpenAlexW4313312072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.